scholarly journals Sensitivity, Specificity and Accuracy of Androgen Deficiency in Ageing Male (ADAM) Questionnaire for the Clinical Detection of Androgen Deficiency in the Male Population in Pakistan

Cureus ◽  
2020 ◽  
Author(s):  
Sidra Naz ◽  
Nikeeta Mandhan ◽  
Prem Shankar ◽  
Kuldeep Raj ◽  
Sidra Memon
Keyword(s):  
Androgen Deficiency ◽  
Male Population ◽  
Ageing Male ◽  
Clinical Detection ◽  
Sensitivity Specificity

scholarly journals Erectile dysfunction – overview from a cardiovascular perspective

VASA ◽  
2017 ◽  
Vol 46 (5) ◽  
pp. 347-353 ◽  
Author(s):  
Frederic Baumann ◽  
Deborah Hehli ◽  
Vladimir Makaloski ◽  
Martin Schumacher ◽  
Heinz Schönhofen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Erectile Dysfunction ◽  
Cardiovascular Risk ◽  
Endovascular Therapy ◽  
Minimal Invasive ◽  
Male Population ◽  
Ageing Male ◽  
The Common ◽  
Diagnostics And Therapy

Abstract. Erectile dysfunction (ED) is an evolving health problem with growing incidence in the ageing male population with potentially predictive value for cardiovascular and other chronic diseases. ED shares the common cardiovascular risk factors. The aetiology of ED is numerous including neurogenic, psychogenic, arteriogenic, and venogenic reasons. The origin of arteriogenic ED is frequently atherosclerosis. Patients not adequately responding to conservative measures including oral medication are often referred to further vascular diagnostics and therapy. At present, the refinements in endovascular therapy allow for minimal-invasive revascularization of erection-related arteries. The role of endovascular therapy in the complex framework of the multifactorial causes of ED requires further scientific scrutiny.

scholarly journals Anti-Inflammatory and Antioxidant Effects of Kelong-Capsule on Testosterone-Induced Benign Prostatic Hyperplasia in Rats

2018 ◽  
Vol 2018 ◽  
pp. 1-8
Author(s):  
Ling Zhang ◽  
Xin-Rong Fan ◽  
Hui Xie ◽  
Qing-Hu He ◽  
Yu-Song Nie ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Common Disease ◽  
Related Factor ◽  
Group Model ◽  
Model Group ◽  
Male Population ◽  
Treatment Groups ◽  
Ageing Male ◽  
Antioxidant Effects

Benign prostatic hyperplasia (BPH) is a common disease in the current ageing male population. This research aims to study the effects of Kelong-Capsules (KLC) on testosterone-induced BPH. Thirty rats were randomly divided into normal group, model group, and three treatment groups. Three treatment groups were given KLC (3.6 g/kg), KLC (7.2 g/kg), and finasteride (0.9 mg/kg), respectively, for 28 days after establishing the animal model. The BPH rat models were evaluated by Traditional Chinese Medicine (TCM) symptoms and prostate index (PI). Results indicated that three treatment groups all alleviated the pathological changes of prostate and kidney at different levels. Compared with the model group, the PI of the groups treated with KLC (7.2 g/kg) and finasteride decreased significantly. The expressions of NF-E2 related factor 2 (Nrf-2) and quinine oxidoreductase (NQO1) in the group treated with KLC (3.6 g/kg) increased markedly (p<0.01). The cyclooxygenase-2 (COX-2) protein expression of the group treated with KLC (7.2 g/kg) was increased (p<0.01). In conclusion, KLC could obviously inhibit the growth of prostate, and KLC (3.6 g/kg) could promote the expressions of Nrf2 and NQO1.

Older Aboriginal men creating a therapeutic Men's Shed: an exploratory study

2019 ◽  
Vol 40 (7) ◽  
pp. 1455-1468 ◽  
Author(s):  
Terrance Cox ◽  
Ha Hoang ◽  
Tony Barnett ◽  
Merylin Cross
Keyword(s):  
Community Based Participatory Research ◽  
Research Approach ◽  
Social Emotional ◽  
Male Population ◽  
Community Environment ◽  
Illness Experiences ◽  
Therapeutic Landscape ◽  
Ageing Male ◽  
To Come

AbstractMen's Sheds are entrenched throughout Australian and international communities due to their popularity in attracting mainly older men to come together and undertake various social and workshop activities. A growing body of research has emerged where men associate regular Shed participation with improved social, emotional and physical wellbeing. However, few studies have examined Aboriginal men's engagement in Men's Sheds. This article reports on a study that investigated how a cohort of older Aboriginal men from one rural Tasmanian community consider the benefits of engaging in their local Shed. A community-based participatory research approach was developed in consultation with Aboriginal community leaders to ensure the study supported the community's expectations. Interview data from ten Aboriginal men combine to represent the Shed environment as an enabling therapeutic landscape, with key themes represented as domains of belonging, hope, mentoring and shared illness experiences. Shed activities were premised on these men co-creating an informal, culturally safe and male-friendly community environment to enjoy the company of other men. The created Shed environment was mutually beneficial as the participants reported improved wellbeing despite living with the effects of declining health and ageing. The findings inform Aboriginal communities and health-care stakeholders to consider the unique role of Men's Sheds for enhancing the health of an ageing male population.

Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population

2006 ◽  
Vol 64 (6) ◽  
pp. 652-658 ◽  
Author(s):  
Marie-Helene Gannage-Yared ◽  
Florence Fares ◽  
Michelle Semaan ◽  
Simon Khalife ◽  
Selim Jambart
Keyword(s):  
Insulin Sensitivity ◽  
Lipid Profile ◽  
Sex Steroids ◽  
Male Population ◽  
Ageing Male

scholarly journals Prevalence of Symptomatic Androgen Deficiency in Men

2007 ◽  
Vol 92 (11) ◽  
pp. 4241-4247 ◽  
Author(s):  
Andre B. Araujo ◽  
Gretchen R. Esche ◽  
Varant Kupelian ◽  
Amy B. O’Donnell ◽  
Thomas G. Travison ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Free Testosterone ◽  
Population Based ◽  
Total Testosterone ◽  
Androgen Deficiency ◽  
Male Population ◽  
Clinical Criteria ◽  
Testosterone Levels ◽  
Low Testosterone ◽  
Osteoporosis Fracture

Abstract Context: Despite recognition that androgen deficiency in men should be defined according to biochemical and clinical criteria, most prevalence estimates are based on low testosterone levels alone. Objective: The objective of this study was to examine the association between symptoms of androgen deficiency and low total and calculated free testosterone levels and estimate the prevalence of symptomatic androgen deficiency in men. Design: This study was a population-based, observational survey. Participants: A total of 1475 Black, Hispanic, and white men, between the ages of 30–79 yr, with complete data on testosterone, SHBG, and symptoms of androgen deficiency, and who are not taking medications that impact sex steroid levels were randomly selected from the Boston Area Community Health Survey. Outcome: Outcomes were measured as symptomatic androgen deficiency, defined as low total (&lt;300 ng/dl) and free (&lt;5 ng/dl) testosterone plus presence of low libido, erectile dysfunction, osteoporosis or fracture, or two or more of following symptoms: sleep disturbance, depressed mood, lethargy, or diminished physical performance. Results: Mean age of the sample was 47.3 ± 12.5 yr. Approximately 24% of subjects had total testosterone less than 300 ng/dl, and 11% of subjects had free testosterone less than 5 ng/dl. Prevalence of symptoms were as follows: low libido (12%), erectile dysfunction (16%), osteoporosis/fracture (1%), and two or more of the nonspecific symptoms (20%). Low testosterone levels were associated with symptoms, but many men with low testosterone levels were asymptomatic (e.g. in men 50+ yr, 47.6%). Crude prevalence of symptomatic androgen deficiency was 5.6% (95% confidence interval: 3.6%, 8.6%), and was not significantly related to race and ethnic group. Prevalence was low in men less than 70 yr (3.1–7.0%) and increased markedly with age to 18.4% among 70 yr olds. Projection of these estimates to the year 2025 suggests that there will be as many as 6.5 million American men ages 30–79 yr with symptomatic androgen deficiency, an increase of 38% from 2000 population estimates. Conclusions: Prevalence of symptomatic androgen deficiency in men 30 and 79 yr of age is 5.6% and increases substantially with age. The aging of the U.S. male population will cause a large increase in the burden of symptomatic androgen deficiency. Future work should address the clinical significance of low testosterone levels in asymptomatic men.

Sign in / Sign up

Export Citation Format

Share Document